Literature DB >> 18258483

Novel strategies to eliminate persistent viral infections.

Marianne M Martinic1, Matthias G von Herrath.   

Abstract

Infection with viruses that have the capacity to modulate or evade the immune response can result in persistence, which can lead to a variety of chronic problems including neoplasia, immunosuppression, autoimmune-like syndromes, and selective organ failure. Recently, two promising new treatment approaches that target either the inhibitory receptor programmed cell death 1 (PD-1) or neutralize interleukin-10 (IL-10) during chronic viral infection have been described. We discuss how future combination therapies can be used to inhibit viral synthesis as well as strengthen the antiviral response without increasing immunopathology or the development of autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258483     DOI: 10.1016/j.it.2007.12.002

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  13 in total

1.  IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection.

Authors:  Galit Alter; Daniel Kavanagh; Suzannah Rihn; Rutger Luteijn; David Brooks; Michael Oldstone; Jan van Lunzen; Marcus Altfeld
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

2.  Antibodies to human IL-10 neutralize ebvIL-10-mediated cytokine suppression but have no effect on cmvIL-10 activity.

Authors:  Noelle D Brodeur; Juliet V Spencer
Journal:  Virus Res       Date:  2010-08-20       Impact factor: 3.303

Review 3.  PD-1 signaling in primary T cells.

Authors:  James L Riley
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

4.  Association of IL-10-promoter genetic variants with the rate of CD4 T-cell loss, IL-10 plasma levels, and breadth of cytotoxic T-cell lymphocyte response during chronic HIV-1 infection.

Authors:  Dshanta D Naicker; Bingxia Wang; Elena Losina; Jennifer Zupkosky; Susan Bryan; Shabashini Reddy; Manjeetha Jaggernath; Mammekwa Mokgoro; Philip J R Goulder; Daniel E Kaufmann; Thumbi Ndung'u
Journal:  Clin Infect Dis       Date:  2011-11-18       Impact factor: 9.079

5.  Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction.

Authors:  Young-June Kim; Su-Jung Park; Hal E Broxmeyer
Journal:  J Immunol       Date:  2011-07-27       Impact factor: 5.422

Review 6.  NKT cell immune responses to viral infection.

Authors:  Marlowe S Tessmer; Ayesha Fatima; Christophe Paget; Francois Trottein; Laurent Brossay
Journal:  Expert Opin Ther Targets       Date:  2009-02       Impact factor: 6.902

7.  Virus-specific host miRNAs: antiviral defenses or promoters of persistent infection?

Authors:  Vinay S Mahajan; Adam Drake; Jianzhu Chen
Journal:  Trends Immunol       Date:  2008-12-06       Impact factor: 16.687

8.  Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function.

Authors:  Zoë Urry; Emmanuel Xystrakis; David F Richards; Joanne McDonald; Zahid Sattar; David J Cousins; Christopher J Corrigan; Emma Hickman; Zarin Brown; Catherine M Hawrylowicz
Journal:  J Clin Invest       Date:  2009-01-12       Impact factor: 14.808

9.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

10.  Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection.

Authors:  Yongwen Chen; Shengxi Wu; Guoning Guo; Lei Fei; Sheng Guo; Chengying Yang; Xiaolan Fu; Yuzhang Wu
Journal:  PLoS Pathog       Date:  2011-07-07       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.